KG002 / Celltrion, Kaigene - LARVOL DELTA

Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases (PRNewswire) - "Under the terms of the agreement, Kaigene will receive $8 million upfront payment and up to $736 million in total milestone payments, including $11 million in near-term milestones through the initiation of Phase 1 clinical trials. Kaigene is also eligible to receive tiered royalties on net sales if the product from the collaboration is commercialized. Celltrion will obtain exclusive rights to develop and commercialize KG006 worldwide except Greater China and Japan, and will hold worldwide rights for KG002."

Licensing / partnership • Immunology